VRDN — Viridian Therapeutics Share Price
0.000.00%
Last trade - 00:00- $830.33m
- $308.90m
- $0.31m
- 36
- 10
- 27
- 14
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.57 | ||
| Price to Tang. Book | 1.57 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2,785.58 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -39.37% | ||
| Return on Equity | -55.69% | ||
| Operating Margin | -82595.14% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4.46 | 1.05 | 2.96 | 1.77 | 0.31 | 0.35 | 0.16 | -48.16% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. It is focused on advancing VRDN-001 as a potential intravenous therapy followed by VRDN-003 as a potential subcutaneous therapy for the treatment of TED. Its advanced program, VRDN-001, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Directors
- Jonathan Violin PRE
- Kristian Humer CFO (46)
- Barrett Katz OTH
- Jennifer Moses DRC (46)
- Peter Harwin IND (35)
- Tomas Kiselak IND
- Arlene Morris IND (69)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- December 8th, 2010
- Public Since
- June 18th, 2014
- No. of Shareholders
- 31
- No. of Employees
- 96
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 63,822,468
- Address
- 221 CRESCENT STREET, BLDG. 17, SUITE 401, WALTHAM, 02453
- Web
- https://www.viridiantherapeutics.com/
- Phone
- +1 6172724600
- Contact
- Louisa Stone
- Auditors
- KPMG LLP
Upcoming Events for VRDN
Q3 2024 Viridian Therapeutics Inc Earnings Release
Similar to VRDN
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Viridian Therapeutics share price?
As of Today at 24:03 UTC, shares in Viridian Therapeutics are trading at $12.57. This share price information is delayed by 15 minutes.
How has the Viridian Therapeutics share price performed this year?
Shares in Viridian Therapeutics last closed at $12.57 and the price had moved by -52.85% over the past 365 days. In terms of relative price strength the Viridian Therapeutics share price has underperformed the S&P500 Index by -62.48% over the past year.
What are the analyst and broker recommendations for Viridian Therapeutics?
The overall consensus recommendation for Viridian Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Viridian Therapeutics dividend yield?
Viridian Therapeutics does not currently pay a dividend.
Does Viridian Therapeutics pay a dividend?
Viridian Therapeutics does not currently pay a dividend.
When does Viridian Therapeutics next pay dividends?
Viridian Therapeutics does not currently pay a dividend.
How do I buy Viridian Therapeutics shares?
To buy shares in Viridian Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Viridian Therapeutics?
As of the previous close price of $12.57, shares in Viridian Therapeutics had a market capitalisation of $802.25m.
Where are Viridian Therapeutics shares listed?
Here are the trading details for Viridian Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: VRDN
What kind of share is Viridian Therapeutics?
Based on an overall assessment of its quality, value and momentum Viridian Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Viridian Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Viridian Therapeutics is $35.19. That is 179.95% above the last closing price of $12.57.
Analysts covering Viridian Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$3.71 for the next financial year.
What is the trend in the Viridian Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Viridian Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -51.1%.
As of the last closing price of $12.57, shares in Viridian Therapeutics were trading -23.52% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Viridian Therapeutics PE Ratio?
The Viridian Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $12.57.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Viridian Therapeutics?
Viridian Therapeutics' management team is headed by:
- Jonathan Violin - PRE
- Kristian Humer - CFO
- Barrett Katz - OTH
- Jennifer Moses - DRC
- Peter Harwin - IND
- Tomas Kiselak - IND
- Arlene Morris - IND